Oral and Oropharyngeal Cancer

Medical Clinics of North America

Volumn 98, Issue 6, 2014, Pages 1299-1321

  Huber, Michaell A ^a   Tantiwongkosi, Bundhit ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Alcohol; Areca nut; Biopsy; HPV; Oral cavity; Oropharynx; Squamous cell carcinoma; Tobacco

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; WART VIRUS VACCINE;

ACTINIC CHEILOSIS; ALCOHOL CONSUMPTION; BETEL NUT; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL EXAMINATION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC EQUIPMENT; DYSPHAGIA; ERYTHROPLASIA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFECTION; LEUKOPLAKIA; MOUTH CANCER; MOUTH DISEASE; MOUTH PAIN; MOUTH ULCER; MUCOSA INFLAMMATION; NONHUMAN; ORAL BIOPSY; ORAL LICHEN PLANUS; ORAL SURGERY; OROPHARYNX CANCER; OTITIS; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND DISEASE; SPEECH DISORDER; SYMPTOM; TOBACCO; TRISMUS; WEIGHT REDUCTION; ARECA; DRINKING BEHAVIOR; INCIDENCE; MOUTH NEOPLASMS; MULTIMODALITY CANCER THERAPY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PRIMARY HEALTH CARE; PROGNOSIS; RISK FACTOR; SMOKING;

ALCOHOL DRINKING; ARECA; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; MOUTH NEOPLASMS; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY HEALTH CARE; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 84925226753     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2014.08.005     Document Type: Review

References (75)

1. National Cancer Institute PDQ® lip and oral cavity cancer treatment 2012, National Cancer Institute, Bethesda (MD), Available at:, Accessed February 5, 2014. http://cancer.gov/cancertopics/pdq/treatment/lip-and-oral-cavity/HealthProfessional.
2. National Cancer Institute PDQ® oropharyngeal cancer treatment 2013, National Cancer Institute, Bethesda (MD), Available at:, Accessed February 5, 2014. http://cancer.gov/cancertopics/pdq/treatment/oropharyngeal/HealthProfessional.
3. Cooper J.S., Porter K., Mallin K., et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009, 31(6):748-758.
4. Jacobson J.J., Epstein J.B., Eichmiller F.C., et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid. Head Neck Oncol 2012, 4:15.
5. Siegel R., Ma J., Zou Z., et al. Cancer statistics, 2014. CA Cancer J Clin 2014, 64(1):9-29.
6. Mignogna M.D., Fedele S., Lo Russo L., et al. Oral and pharyngeal cancer: lack of prevention and early detection by health care providers. Eur J Cancer Prev 2001, 10(4):381-383.
7. Gomez I., Warnakulasuriya S., Varela-Centelles P.I., et al. Is early diagnosis of oral cancer a feasible objective? Who is to blame for diagnostic delay?. Oral Dis 2010, 16(4):333-342.
8. Pleis J.R., Ward B.W., Lucas J.W. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. Vital Health Stat 10 2010, (249):1-207.
9. Greer R.O. Oral manifestations of smokeless tobacco use. Otolaryngol Clin North Am 2011, 44(1):31-56. v.
10. Sharan R.N., Mehrotra R., Choudhury Y., et al. Association of betel nut with carcinogenesis: revisit with a clinical perspective. PLoS One 2012, 7(8):e42759.
11. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol 2009, 45(4-5):317-323.
12. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncol 2010, 46(6):423-425.
13. Vieira R.A., Minicucci E.M., Marques M.E., et al. Actinic cheilitis and squamous cell carcinoma of the lip: clinical, histopathological and immunogenetic aspects. An Bras Dermatol 2012, 87(1):105-114.
14. Warnakulasuriya S., Johnson N.W., van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. JOral Pathol Med 2007, 36(10):575-580.
15. Pindborg J.J., Reichart P.A., Smith C.J., et al. Histological typing of cancer and precancer of the oral mucosa. 2nd edition 1997, Springer Verlag, Berlin.
16. Lingen M.W., Pinto A., Mendes R.A., et al. Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis 2011, 17(Suppl 1):7-22.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
18. Howard J.D., Lu B., Chung C.H. Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation. Oral Oncol 2012, 48(1):10-17.
19. Haddad R.I., Shin D.M. Recent advances in head and neck cancer. NEngl J Med 2008, 359(11):1143-1154.
20. Choi S., Myers J.N. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. JDent Res 2008, 87(1):14-32.
21. Gasche J.A., Goel A. Epigenetic mechanisms in oral carcinogenesis. Future Oncol 2012, 8(11):1407-1425.
22. Oliveira L.R., Ribeiro-Silva A. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2011, 40(3):298-307.
23. Shiraki M., Odajima T., Ikeda T., et al. Combined expression of p53, cyclin D1 and epidermal growth factor receptor improves estimation of prognosis in curatively resected oral cancer. Mod Pathol 2005, 18(11):1482-1489.
24. Zheng M., Li L., Tang Y.L., et al. Biomarkers in tongue cancer: understanding the molecular basis and their clinical implications. Postgrad Med J 2010, 86(1015):292-298.
25. Petti S. Lifestyle risk factors for oral cancer. Oral Oncol 2009, 45(4-5):340-350.
26. Saman D.M. Areview of the epidemiology of oral and pharyngeal carcinoma: update. Head Neck Oncol 2012, 4:1.
27. Sivasithamparam J., Visk C.A., Cohen E.E., et al. Modifiable risk behaviors in patients with head and neck cancer. Cancer 2013, 119(13):2419-2426.
28. Warnakulasuriya S. Causes of oral cancer-an appraisal of controversies. Br Dent J 2009, 207(10):471-475.
29. Goldstein B.Y., Chang S.C., Hashibe M., et al. Alcohol consumption and cancers of the oral cavity and pharynx from 1988 to 2009: an update. Eur J Cancer Prev 2010, 19(6):431-465.
30. de Visscher J.G., van der Waal I. Etiology of cancer of the lip. A review. Int J Oral Maxillofac Surg 1998, 27(3):199-203.
31. Gillison M.L., Broutian T., Pickard R.K., et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012, 307(7):693-703.
32. Pickard R.K., Xiao W., Broutian T.R., et al. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis 2012, 39(7):559-566.
33. Rautava J., Syrjanen S. Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol 2012, 6(Suppl 1):S3-S15.
34. Shaw R., Robinson M. The increasing clinical relevance of human papillomavirus type 16 (HPV-16) infection in oropharyngeal cancer. Br J Oral Maxillofac Surg 2011, 49(6):423-429.
35. Tribius S., Hoffmann M. Human papilloma virus infection in head and neck cancer. Dtsch Arztebl Int 2013, 110(11):184-190. 90e1.
36. Demarosi F., Lodi G., Carrassi A., et al. Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 2005, 41(9):865-877.
37. Dasanayake A.P., Silverman A.J., Warnakulasuriya S. Mate drinking and oral and oro-pharyngeal cancer: a systematic review and meta-analysis. Oral Oncol 2010, 46(2):82-86.
38. Conway D.I., Petticrew M., Marlborough H., et al. Socioeconomic inequalities and oral cancer risk: a systematic review and meta-analysis of case-control studies. Int J Cancer 2008, 122(12):2811-2819.
39. Blot W.J., McLaughlin J.K., Winn D.M., et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988, 48(11):3282-3287.
40. Jeng J.H., Chang M.C., Hahn L.J. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 2001, 37(6):477-492.
41. Warnakulasuriya S. Living with oral cancer: epidemiology with particular reference to prevalence and life-style changes that influence survival. Oral Oncol 2010, 46(6):407-410.
42. Marron M., Boffetta P., Zhang Z.F., et al. Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol 2010, 39(1):182-196.
43. Herrero R., Quint W., Hildesheim A., et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013, 8(7):e68329.
44. Food and Drug Administration. Gardasil [package insert]. Available at: Accessed February 5, 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf.
45. Food and Drug Administration. Cervarix [package insert and patient information]. Available at: Accessed February 5, 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf.
46. Diaz M.L. Counseling the patient with HPV disease. Obstet Gynecol Clin North Am 2013, 40(2):391-402.
47. World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2012: Latest world cancer statistics. 2014. Available at: Accessed February 5, 2014. http://globocan.iarc.fr/Default.aspx.
48. National Cancer Institute. SEER stat fact sheets: oral cavity and pharynx cancer. Available at: Accessed February 7, 2014. http://seer.cancer.gov/statfacts/html/oralcav.html.
49. Marur S., D'Souza G., Westra W.H., et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11(8):781-789.
50. Cleveland J.L., Junger M.L., Saraiya M., et al. The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States: implications for dentistry. JAm Dent Assoc 2011, 142(8):915-924.
51. Huber M.A. Adjunctive diagnostic aids in oral cancer screening: an update. Tex Dent J 2012, 129(5):471-480.
52. Food and Drug Administration. 510(k) Premarket notification - MicroLux DL, MicroLux BLU, Bio/Screen - K121282. Available at: Accessed February 8, 2014. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K121282.
53. Food and Drug Administration. 510(k) Premarket notification - OralID - K123169. Available at: Accessed February 8, 2014. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K123169.
54. Rethman M.P., Carpenter W., Cohen E.E., et al. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. JAm Dent Assoc 2010, 141(5):509-520.
55. Edge S.B., Byrd D.R., Compton C.C., et al. AJCC cancer staging manual 2010, Springer, New York. 7th edition.
56. Trotta B.M., Pease C.S., Rasamny J.J., et al. Oral cavity and oropharyngeal squamous cell cancer: key imaging findings for staging and treatment planning. Radiographics 2011, 31(2):339-354.
57. Skinner H.D., Holsinger F.C., Beadle B.M. Oropharynx cancer. Curr Probl Cancer 2012, 36(6):334-415.
58. Takes R.P., Rinaldo A., Silver C.E., et al. Future of the TNM classification and staging system in head and neck cancer. Head Neck 2010, 32(12):1693-1711.
59. Angadi P.V., Savitha J.K., Rao S.S., et al. Oral field cancerization: current evidence and future perspectives. Oral Maxillofac Surg 2012, 16(2):171-180.
60. Hanna G.J., Haddad R.I., Lorch J.H. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future?. Oncologist 2013, 18(3):288-293.
61. Licitra L., Grandi C., Guzzo M., et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. JClin Oncol 2003, 21(2):327-333.
62. Duvvuri U., Myers J.N. Contemporary management of oropharyngeal cancer: anatomy and physiology of the oropharynx. Curr Probl Surg 2009, 46(2):119-184.
63. Furness S., Glenny A.M., Worthington H.V., et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2011, (4). CD006386.
64. Haigentz M., Silver C.E., Corry J., et al. Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009, 266(12):1845-1855.
65. Epstein J.B., Thariat J., Bensadoun R.J., et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012, 62(6):400-422.
66. National Cancer Institute PDQ® oral complications of chemotherapy and head/neck radiation 2013, National Cancer Institute, Bethesda (MD), Available at:, Accessed February 5, 2014. http://cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional.
67. Wang X., Hu C., Eisbruch A. Organ-sparing radiation therapy for head and neck cancer. Nat Rev Clin Oncol 2011, 8(11):639-648.
68. Lodi G., Porter S. Management of potentially malignant disorders: evidence and critique. JOral Pathol Med 2008, 37(2):63-69.
69. Vladimirov B.S., Schiodt M. The effect of quitting smoking on the risk of unfavorable events after surgical treatment of oral potentially malignant lesions. Int J Oral Maxillofac Surg 2009, 38(11):1188-1193.
70. Dost F., Le Cao K., Ford P.J., et al. Malignant transformation of oral epithelial dysplasia: a real-world evaluation of histopathologic grading. Oral Surg Oral Med Oral Pathol Oral Radiol 2014, 117(3):343-352.
71. Holmstrup P., Vedtofte P., Reibel J., et al. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006, 42(5):461-474.
72. William W.N. Oral premalignant lesions: any progress with systemic therapies?. Curr Opin Oncol 2012, 24(3):205-210.
73. Gonzalez-Moles M.A., Scully C., Ruiz-Avila I. Molecular findings in oral premalignant fields: update on their diagnostic and clinical implications. Oral Dis 2012, 18(1):40-47.
74. Gritz E.R., Demark-Wahnefried W. Health behaviors influence cancer survival. JClin Oncol 2009, 27(12):1930-1932.
75. Fiore M.C., Jaén C.R., Baker T.B., et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline 2008, US Department of Health and Human Services. Public Health Service, Rockville (MD), Available at:, Accessed February 5, 2014. http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/treating_tobacco_use08.pdf.